A randomized study of two dose levels of intravenous (IV) clofarabibe (CLO) in the treatment of patients (pts) with higher-risk myelodysplastic syndrome (MDS)

被引：0
|
作者：
Jabbour, E. [1 ]
Kantarjian, H. [1 ]
Garcia-Manero, G. [1 ]
Kashani, F. Ravandi [1 ]
Borthakur, G. [1 ]
Estrov, Z. [1 ]
Gandhi, V. [1 ]
Byrd, A. [1 ]
Kwari, M. [1 ]
Faderi, S. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.6504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6504
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Counseling Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Regarding Expected Survival with Azacitidine (aza) Therapy: Are We Using Accurate Estimates?
    Deveaux, Michelle
    Stahl, Maximilian
    Giri, Smith
    Wang, Rong
    Podoltsev, Nikolai A.
    Ma, Xiaomei
    Zeidan, Amer M.
    [J]. BLOOD, 2017, 130
  • [42] RANDOMIZED PHASE III STUDY OF IV RIGOSERTIB VERSUS BEST SUPPORTIVE CARE (BSC) IN PATIENTS WITH HIGHER-RISK MDS (HR-MDS) AFTER FAILURE OF HYPOMETHYLATING AGENTS (HMAS)
    Garcia-Manero, G.
    Fenaux, P.
    Al-Kali, A.
    Baer, M. R.
    Sekeres, M.
    Roboz, G.
    Gaidano, G.
    Scott, B.
    Greenberg, P.
    Platzbecker, U.
    Steensma, D. P.
    Kambhampati, S.
    Kreuzer, K. A.
    Godley, L.
    Collins, R.
    Atallah, E.
    Azarnia, N.
    Petrone, M. E.
    Snyder, B. R.
    Maniar, M.
    Silverman, L. R.
    [J]. LEUKEMIA RESEARCH, 2015, 39 : S57 - S58
  • [43] TREATMENT OF HIGHER-RISK MYELODYSPLASTIC SYNDROME (MDS) WITH AZACITIDINE: A 4-YEAR POPULATION-BASED ANALYSIS FROM BRITISH COLUMBIA, CANADA
    Ankenman, M.
    Hogge, D.
    Narayanan, S.
    Power, M.
    Abou Mourad, Y.
    Barnett, M.
    Nantel, S.
    Sutherland, H.
    Forrest, D.
    Broady, R.
    Toze, C.
    Gerrie, A.
    Song, K.
    Nevill, T.
    [J]. HAEMATOLOGICA, 2015, 100 : 240 - 241
  • [44] Preliminary Results from a Phase II Study of the Combination of Azacitidine and Pembrolizumab in Patients with Higher-Risk Myelodysplastic Syndrome
    Chien, Kelly S.
    Cortes, Jorge E.
    Borthakur, Gautam
    DiNardo, Courtney D.
    Daver, Naval G.
    Jain, Nitin
    Naqvi, Kiran
    Jabbour, Elias J.
    Sheppard, Kimberly B.
    Pierce, Sherry A.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    [J]. BLOOD, 2018, 132
  • [45] Intravenous voriconazole (IV-VORI) prevents invasive fungal infections (IFI) in patients (pts) with acute myelogenous leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
    Mattiuzzi, GN
    Alvarado, G
    Kantarjian, HM
    Verstovsek, S
    Cabanillas, M
    Faderl, S
    Lim, JT
    Giles, F
    Beran, M
    O'Brien, S
    Estey, EH
    [J]. BLOOD, 2004, 104 (11) : 253A - 253A
  • [46] Phase 2 Expansion Study of Oral Rigosertib Combined with Azacitidine (AZA) in Patients (Pts) with Higher-Risk (HR) Myelodysplastic Syndromes (MDS): Efficacy and Safety Results in HMA Treatment Naive & Relapsed (Rel)/Refractory (Ref) Patients
    Navada, Shyamala C.
    Garcia-Manero, Guillermo
    Atallah, Ehab L.
    Rajeh, M. Nabeel
    Shammo, Jamile M.
    Griffiths, Elizabeth A.
    Khaled, Samer K.
    Dakhil, Shaker R.
    Young, David E.
    Odchimar-Reissig, Rosalie
    Pemmaraju, Naveen
    Alvarado, Yesid
    Ohanian, Maro N.
    John, Rosmy B.
    Zbyszewski, Patrick S.
    Maniar, Manoj
    Petrone, Michael E.
    Fruchtman, Steven M.
    Silverman, Lewis R.
    [J]. BLOOD, 2018, 132
  • [47] Impact of Type of Hypomethylating Agent (HMA) Used on Outcomes of Patients (Pts) with Higher-Risk Myelodysplastic Syndromes/Neoplasms (HR-MDS) - a Large, Multicenter, Retrospective Analysis
    Bewersdorf, Philipp
    Kewan, Tariq
    Blaha, Ondrej
    Stahl, Maximilian
    Al Ali, Najla H.
    DeZern, Amy E.
    Sekeres, Mikkael A.
    Uy, Geoffrey L.
    Carraway, Hetty E.
    Desai, Pinkal
    Griffiths, Elizabeth A.
    Stein, Eytan M.
    Brunner, Andrew M.
    McMahon, Christine M.
    Zeidner, Joshua F.
    Savona, Michael R.
    Stempel, Jessica M.
    Chandhok, Namrata Sonia
    Ramaswamy, Rahul
    Roboz, Gail J.
    Rolles, Benjamin
    Wang, Eunice S.
    Harris, Amyah C.
    Amaya, Maria L.
    Hawkins, Hayley
    Grenet, Justin
    Gurnari, Carmelo
    Shallis, Rory M.
    Xie, Zhuoer
    Maciejewski, Jaroslaw P.
    Sallman, David A.
    Della Porta, Matteo Giovanni
    Komrokji, Rami S.
    Zeidan, Amer M.
    [J]. BLOOD, 2023, 142
  • [48] Genomic Profiling in Patients with Higher-Risk Myelodysplastic Syndrome (HR-MDS) Following HMA Failure: Baseline Results from the Inspire Study (04-30)
    Garcia-Manero, Guillermo
    Jonasova, Anna
    Luger, Selina M.
    Al-Kali, Aref
    Valcarcel, David
    Warlick, Erica D.
    Jedrzejczak, Wieslaw W.
    Diez-Campelo, Maria
    Zbyszewski, Patrick S.
    Cavanaugh, Christopher
    Woodman, Richard C.
    Fruchtman, Steven M.
    Takahashi, Koichi
    [J]. BLOOD, 2019, 134
  • [49] Clinical Outcome of 40 Patients with Higher-Risk Myelodysplastic Syndromes (MDS) after Treatment with Hypomethylating Agents: a Matched-Pairs Analysis.
    Nachtkamp, Kathrin
    Strupp, Corinna
    Kuendgen, Andrea
    Gattermann, Norbert
    Haas, Rainer
    Germing, Ulrich
    [J]. BLOOD, 2008, 112 (11) : 929 - 929
  • [50] INSPIRE: A randomized phase III trial of intravenous rigosertib in patients with higher-risk myelodysplastic syndromes (HR-MDS) after failure of hypomethylating agents (HMAs) Study design informed by subgroup analyses of ONTIME.
    Garcia-Manero, Guillermo
    Al-Kali, Aref
    Baer, Maria R.
    Robor, Gail J.
    Platzbecker, Uwe
    Kambhampati, Suman
    Godley, Lucy A.
    Collins, Robert
    Shammo, Jamile M.
    Santini, Valeria
    Raza, Azra
    Silverman, Lewis R.
    Azarnia, Nozar
    Fruchtman, Steven M.
    Snyder, Barbara R.
    Fenaux, Pierre
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
12345